This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Siemens To Create Companion Diagnostic Test For In-Development Janssen Heart Failure Drug

Stocks in this article: SI

Today, Siemens Healthcare Diagnostics announces its entrance into a collaboration with Janssen Pharmaceutica NV to design, develop and commercialize a companion diagnostic test associated with an early-stage compound being developed by Janssen. This compound targets autoantibodies directed against the human β1-adrenergic receptor (β1-AR) that may contribute to the development of heart failure.

Under the agreement, Siemens will work with Janssen to design immunoassay-based companion diagnostic tests for use in Janssen's clinical studies. The Siemens Clinical Laboratory (SCL), an innovative and high-complexity testing laboratory designed to advance personalized medicine, will develop the clinical trial assay that will be used in Janssen’s clinical trials. In parallel, Siemens will develop and validate an in vitro diagnostic test as a companion diagnostic for the Janssen therapeutic product. The companion diagnostic test will be broadly commercialized on Siemens' central laboratory automated immunoassay systems.

Heart failure is generally a progressive disease characterized by the heart muscle’s inability to adequately pump oxygenated blood through the body. An estimated 23 million people around the world have been diagnosed with heart failure, a number that is projected to increase.¹ For most causes of heart failure, there is no known cure.

“Our relationship with Janssen marks an important next step in Siemens’ personalized medicine strategy,” said Michael Reitermann, CEO, Siemens Healthcare Diagnostics. “As a leading clinical diagnostics company, with the tools and technologies to help define the future of patient care, we are looking forward to collaborating with Janssen and extending their position in cardiac therapies.”

¹Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J 2001;22:623-6.

Launched in November 2011, “Agenda 2013” is the initiative of the Siemens Healthcare Sector to further strengthen its innovative power and competitiveness. Specific measures, which will be implemented by the end of 2013, have been defined in four fields of action: innovation, competitiveness, regional footprint, and people development.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs